REP 2139

Drug Profile

REP 2139

Alternative Names: REP 2139; REP 2139 calcium chelate; REP 2139 magnesium chelate; REP 2139-Ca; REP 2139-Mg; REP 9AC'

Latest Information Update: 10 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator REPLICor
  • Class Antivirals; Nucleic acids; Oligonucleotides; Polymers
  • Mechanism of Action Hepatitis B virus replication inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis B; Hepatitis D

Most Recent Events

  • 12 Jun 2017 Pharmacokinetics and safety data from a preclinical trials in Hepatitis B released by Replicor
  • 01 May 2017 REPLICor completes a phase II trial for Hepatitis B and Hepatitis D (Combination therapy) in Moldova (IV, Infusion) (NCT02233075)
  • 19 Apr 2017 Efficacy data from the phase I/II in Hepatitis B infection presented at The International Liver Congress 2017 (ILC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top